Dementia Flashcards
Most common type of dementia
Alzheimers dementia
History of Alzheimers
Preclinical (30yrs) -> Mild cognitive impairment(5yrs) ->
Dementia (9-10yrs)
Pathological features of AD
Medial temporal atrophy
60-90% of AD have vascular lesions
Plaques, NFT, synaptic and neuronal loss (Hirano bodies)
Congophilic angiopathy(90%)-superficial siderosis
Inclusions in AD
APP(amyloid precursor protein) Chr 21
Beta-amyloid oligomers, fibrillar beta amyloid forms plaques. Tau pathology secondary to beta amyloid accumulation
Important genes in AD
PSEN1, PSEN2, APP, APOE4(Chr 19), ADAM 10
Genetic factor in early onset familial AD
APP mutation on Chr 21
Presenilin 1 on Chr 14
Presenilin 2 on Chr 1
Mutation causing decreased risk of AD
Icelandic A673T mutation
ApoE4 in AD
Decreases age of onset by 10% per E4 allele
Enviornmental risk factors for AD
Age, family history, female sex/ single,cardiovascular risk factors
Low education,socialisation, physical inactivity, mid life depression
Protective factors
Physical exercise , ?education
Neurodegenerative markers in AD
CSF -High t-tau, p-tau
SPECT -Parieto temporal hypoperfusion
FDG PET- Precuneus, parieto temporal hypometabolism
MRI - Hippocampal atrophy (specific sign)
Primary age related taupathy (PART)
Relatively benign
Predominantly NFT
Asymptomatic to mild amnesia
MRI -temporal lobe atrophy
Features of AGD (Argyrophilic grain disease)
Tauopathy - 4-R Tau predominant spindle shaped grains in hippocampus and amygdala
Relatively well preserved cognition
Personality changes characterised by emotional disorder involving aggression
HS -Aging
Sclerosing of one or both hippocampus
Rapid forgetting pattern of episodic memory
PET Scan resembles AD
Prevalence exponentially increases with aging
Prevention of AD
In MCI home based exercise regime -> improvement in cognition, aerobic exercise
Mediterranean diet -possibly effective
NSAIDS, Estrogen, fish oil,Vitamin E, statin,ginko biloba - not effective
Souvenaid -medical food supplement in AD
Decreases hippocampal Atrophy
Decreased functional decline
Treatment for AD
Acetylcholinesterase inhibitors-donepezil, rivastigmine, galantamine
CI -asthma, peptic ulcer, conduction defects
S/E : GIT, insomnia, cholinergic
Memantine- Non competitive NMDA antagonist
Moderate to severe AD
S/E: Drowsiness
Aducanumab in AD
Human monoclonal ab for aggregated forms of Abeta amyloid
Fronto temporal dementia
Second commonest young onset dementia
Can have spectrum of continuity with MND
Behavioural variant more common
Non fluent variant linked to CBD,PSP
FTD pathology
50% - TDP 43
50% - Tau
Genetics in FTD
Upto 30% positive family history
Chr 17 -microtubule-associated protein
progranulin gene(associated with wound healing)
Chr 9- C9ORF 72 -single most imp mutation
Psychosis common
Clinical features of behavioural variant of FTD
Disinhibition, apathy, loss of empathy
Hyprorality
Perseverative, stereotypic, ritualistic behaviour